Oligonucleotide Synthesis Market Overview

Oligonucleotides represent one of the fastest growing segments of the pharmaceutical industry. This can be attributed to the rapid pace of innovation in this field, driven by the need for effective and personalized pharmacological interventions.

The global oligonucleotide synthesis market size is estimated to be worth $ 4.8 billion in 2024 and is expected to grow at compounded annual growth rate (CAGR) of 9.9% during the forecast period 2024-2035.

Although oligonucleotides offer significant profit margins and have demonstrated the potential to treat a myriad of disease indications, they are generally associated with high costs of development and complex manufacturing protocols. This has compelled many oligonucleotide therapeutics developers to outsource various aspect of their operations to oligonucleotide synthesis providers.

Oligonucleotide Synthesis Market Segmentation

The oligonucleotide Synthesis Market focuses on Application Area (Research and Diagnostics, and Therapeutics), Type of Product Synthesized (Active Pharmaceutical Ingredients and Finished Dosage Forms), Type of Oligonucleotide Synthesized (Antisense, DNA, siRNA and Other Oligonucleotides), Scale of Operation (Clinical and Commercial), Therapeutic Area (Cardiovascular Disorders, Genetic Disorders, Liver Disorders, Rare Diseases, and Other Disorders), End-Users (Pharmaceutical / Biopharmaceutical Companies, Academic and Research Institutes, and Hospitals), Company Size (Small, Mid-sized, and Large and Very Large) and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World).

This domain is presently characterized by the presence of both niche, specialty oligonucleotide synthesis companies, focused on early-stage development and production (preclinical and / or clinical scales), and one-stop-shops, which have, over time, acquired an extensive range of capabilities to cater to essentially all the product development and commercialization requirements of sponsors.

The global demand for oligonucleotides in 2024 is estimated to grow at an annualized growth rate (CAGR) of 17%. The significant upsurge in the overall demand for such products can be attributed to the fact that patents for some of the drugs are likely to expire in the coming few years, and consequently, several biosimilars are anticipated to be approved in the mid-long term, enabling an exponential increase in the overall demand for oligonucleotides.

Oligonucleotide Synthesis Market Key Companies

Examples of key oligonucleotide synthesis companies include Agilent Technologies, Ajinomoto Bio-Pharma Services, CordenPharma, Creative Biolabs, Ella Biotech, Eurofins Genomics, Future synthesis, Integrated DNA Technologies, Kaneka Eurogentec, LGC Biosearch Technologies, Microsynth, Nitto Avecia, Merck, Ribo Biotechnology, STA Pharmaceutical, Sumitomo Chemical, Thermo Fisher Scientific, TriLink Biotechnologies.  Further, the rising in the clinical demand can be attributed to the rising number of patients enrolled in clinical trials for evaluating oligonucleotides. Increase in the number can be attributed to the ability of these oligonucleotides to treat various indications, such as metabolic disorders and oncological disorders.

Driven by the overall growth of the oligonucleotide-based therapeutics industry, technological advancements and an increasing trend of outsourcing, the market is anticipated to witness a steady growth in the coming decade. In 2024, the maximum revenue generated in this domain is likely to be driven by antisense oligonucleotides, this trend is likely to change in the foreseen future. Presently, 43% of the market share is captured by rare diseases, followed by 19% by  liver disorders and 18% by genetic disorders.

This trend is unlikely to change in the foreseen future. It is worth mentioning the markets in North America and Europe are likely to capture around 75% of the overall share. Further, the market share of Asia-Pacific is anticipated to grow at a relatively faster pace of about 10.7% during the given period.

Browse Complete Report at: https://www.rootsanalysis.com/reports/oligonucleotide-synthesis/304.html

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture catalysts, and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serving our clients in the best possible way.

The research efforts are driven by a global team. The leadership team brings a wealth of experience within the sector. Their collective experience in pharmaceutical / affiliated domains allows us to tackle various areas of research in a structured way. We also regularly leverage our global network of experts who hold senior leadership positions in reputed firms and organizations worldwide.

All our analysts are trained to produce high-quality research work. They are continuously mentored by senior experts to present an original, unbiased and informed perspective on pressing issues in the industry. On any particular subject, we bring together the best available resources to ensure highest quality in all our reports.

Contact Details

Roots Analysis 

Gaurav Chaudhary

+1 (415) 800 3415

+44 (122) 391 1091

Gaurav.chaudhary@rootsanalysis.com 

Website: https://www.rootsanalysis.com/